Network Modeling Identifies Patient-specific Pathways in Glioblastoma.

Download

10.1038:srep28668.pdf

Date

2016-06-29

Author

Tunçbağ, Nurcan
POKORNY, JL
JOHNSON, H
SIO, TT
DALIN, S
IYEKEGBE, DO
WHITE, FM
SARKARIA, JN
FRAENKEL, E

Metadata

Show full item record

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Item Usage Stats

134
views

97
downloads

Glioblastoma is the most aggressive type of malignant human brain tumor. Molecular profiling experiments have revealed that these tumors are extremely heterogeneous. This heterogeneity is one of the principal challenges for developing targeted therapies. We hypothesize that despite the diverse molecular profiles, it might still be possible to identify common signaling changes that could be targeted in some or all tumors. Using a network modeling approach, we reconstruct the altered signaling pathways from tumor-specific phosphoproteomic data and known protein-protein interactions. We then develop a network-based strategy for identifying tumor specific proteins and pathways that were predicted by the models but not directly observed in the experiments. Among these hidden targets, we show that the ERK activator kinase1 (MEK1) displays increased phosphorylation in all tumors. By contrast, protein numb homolog (NUMB) is present only in the subset of the tumors that are the most invasive. Additionally, increased S100A4 is associated with only one of the tumors. Overall, our results demonstrate that despite the heterogeneity of the proteomic data, network models can identify common or tumor specific pathway-level changes. These results represent an important proof of principle that can improve the target selection process for tumor specific treatments.

Subject Keywords

CANCER, EXPRESSION, S100A4, GROWTH, EGFR, NUMB, SENSITIVITY, INFERENCE

URI

https://hdl.handle.net/11511/31461

Journal

Scientific reports

DOI

https://doi.org/10.1038/srep28668

Collections

Graduate School of Informatics, Article

Suggestions

OpenMETU
Core

3D spatial organization and network-guided comparison of mutation profiles in glioblastoma Dinçer, Cansu; Tunçbağ, Nurcan; Department of Bioinformatics (2019) Glioblastoma multiforme (GBM) is the most aggressive and heterogeneous type of brain tumor. The heterogeneity of GBM is the main obstacle to develop effective treatment strategies. In this study, we aimed to decrease the heterogeneity among GBM patients from The Cancer Genome Atlas (TCGA), classify the patients and propose therapeutic hypothesis for patient groups by using patient mutation profiles. We therefore implemented a systems level approach to mutations using their biophysical characteristics and or...
3D spatial organization and network-guided comparison of mutation profiles in Glioblastoma reveals similarities across patients Dincer, Cansu; Kaya, Tugba; Keskin, Ozlem; Gursoy, Attila; Tunçbağ, Nurcan (2019-09-01) Glioblastoma multiforme (GBM) is the most aggressive type of brain tumor. Molecular heterogeneity is a hallmark of GBM tumors that is a barrier in developing treatment strategies. In this study, we used the nonsynonymous mutations of GBM tumors deposited in The Cancer Genome Atlas (TCGA) and applied a systems level approach based on biophysical characteristics of mutations and their organization in patient-specific subnetworks to reduce inter-patient heterogeneity and to gain potential clinically relevant i...
Network-based in silico modeling for drug repurposing and in vitro validation in hepatocellular carcinoma Nalbat, Esra; Tunçbağ, Nurcan; Cetin-Atalay, Rengul (Orta Doğu Teknik Üniversitesi Enformatik Enstitüsü; 2022-10) Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed cancer and a leading cause of death worldwide. The hyperactivated cell survival signaling pathways cause resistance to conventional chemotherapeutics so that targeted therapies could extend patient survival for only a few months. Furthermore, there are limited chemotherapeutics for HCC patients due to impaired liver functions. Thus, it is vital to determine repurposed drugs and drug combinations in HCC treatment.
Network-based discovery of molecular targeted agent treatments in hepatocellular carcinoma Fayetörbay, Rumeys; Tunçbağ, Nurcan; Department of Bioinformatics (2020) Hepatocellular carcinoma (HCC) is one of the most-deadly cancers and the most common type of primary liver cancer. Multikinase inhibitor Sorafenib is one of FDA approved targeted agents in HCC treatment. PI3K/AKT/mTOR pathway is altered in about 51% of HCC; hence, understanding how Sorafenib and PI3K/AKT/mTOR pathway inhibitors act at signaling level is crucial for targeted therapies and to reveal the off-target effects. In this work, we use gene expression profiles (GEPs) of HCC cells (Huh7 and Mahlavu) wh...
Bioinformatic prediction and coexpression network identifies repurposed novel drugs for papillary thyroid cancer Temiz, Kubra (Orta Doğu Teknik Üniversitesi Enformatik Enstitüsü; 2022-10) Thyroid cancer is a type of cancer that affects the endocrine system and has a high malignancy. Papillary thyroid cancer, the most common subtype of thyroid cancer, also has well-differentiated features. Early diagnosed and well-differentiated thyroid cancer is generally associated with a good prognosis and/or survival rate. Therefore, it is of great importance to determine the molecular signatures of the disease. In this study, five papillary thyroid cancer-related gene expression datasets were analyzed us...

Citation Formats

N. Tunçbağ et al., “Network Modeling Identifies Patient-specific Pathways in Glioblastoma.,” Scientific reports, pp. 28668–28668, 2016, Accessed: 00, 2020. [Online]. Available: https://hdl.handle.net/11511/31461.